Predicting responses to immunotherapy

A technology for response and therapy, applied in flow cytometry, cell sorting and related technologies, which can solve problems such as expensive

Pending Publication Date: 2020-06-26
IMMUNESIGNATURES PTY LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these therapies are currently ineffective in a significant percentage of patients, cause significant side effects, and are prohibitively expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Predicting responses to immunotherapy
  • Predicting responses to immunotherapy
  • Predicting responses to immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0106] Preparation of Positive Reaction Control

[0107] The invention may include the additional step of evaluating one or more organs or tissues of an individual who has received an immunomodulator to determine regression of the tumor in said individual, thereby determining whether said individual is suitable to provide a positive response control. For example, where the method is used to predict the likelihood of a complete response, the step includes assessing whether a candidate individual for providing a positive response control has responded completely or partially, or whether there is any response at all. In one embodiment, the step utilizes radiographic imaging to determine the location and volume of each of a plurality of tumor foci in the subject following treatment with the immunomodulator. For example, this may involve a three-dimensional radiological image of the subject showing the geographic location of each of the plurality of tumor lesions. Non-limiting e...

Embodiment 1

[0181] Example 1: Determining the distribution of cells in a sample

[0182] Peripheral blood samples are obtained using venipuncture and the blood is collected into tubes that prevent clotting (eg, tubes containing EDTA or heparin). The leukocytes are then immediately prepared for cell counting, or frozen for long-term storage, such as at -80 or in liquid nitrogen. Cryopreserved leukocytes were thawed prior to analysis using conventional techniques.

[0183] The distribution of cells is determined using techniques that identify the expression of predetermined proteins or transcripts within each individual cell in the sample. Typically, cells are treated with a mixture of 10 to 40 antibodies, each specific for a single cellular protein and labeled with a unique metal isotope or fluorescent dye, allowing the treated cells to be analyzed using mass cytometry or fluorescent cytometry, respectively. Samples are analyzed.

[0184] In the examples provided, cells were treated w...

Embodiment 2

[0226] Example 2: Comparing the distribution of cell populations in different individuals.

[0227] This can be achieved with many statistical techniques including machine learning. A technique based on microarray analysis is presented here.

[0228] Load the percentage data for all individuals to be compared into a microarray analysis software package such as MeV. Row normalization is performed so that the relative weight of each cell population within the dataset is equal to the relative weight of every other population.

[0229] The graph output after row normalization is as follows figure 1 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to methods for determining the likelihood of the formation of a clinical response in an individual to therapy with an immunomodulatory agent for treatment of a disease or condition of the individual.

Description

[0001] field of invention [0002] The present invention relates to immunomodulators, such as checkpoint inhibitors, for use in the treatment of cancer and related diseases and disorders, to the use of such immunomodulators in the treatment of cancer and related disorders, and to flow cytometry, cell sorting and related technologies. Background technique [0003] Reference to any prior art in the specification is not an acknowledgment or implication that such prior art forms part of the common general knowledge in any jurisdiction, or that it could reasonably be expected to be understood by a person skilled in the art, considered to be related and / or combined with other prior art. [0004] Immunotherapy for cancer has been brought into mainstream clinical practice for the first time through the introduction of immunomodulators, including "checkpoint inhibitors." However, these therapies are currently ineffective in a significant percentage of patients, cause significant side...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/48G01N33/574G01N33/573C07K16/28
CPCG01N33/56972G01N2800/52G01N33/56966G01N33/57423G01N33/5743G01N2333/70503G01N2333/70521G01N33/57484C07K16/28C07K16/2818G01N33/5091G01N33/5094
Inventor B·法泽卡斯德斯特格罗思
Owner IMMUNESIGNATURES PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products